Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial
- Submitting institution
-
The University of Leicester
- Unit of assessment
- 1 - Clinical Medicine
- Output identifier
- 5
- Type
- D - Journal article
- DOI
-
10.1016/S2213-2600(18)30201-7
- Title of journal
- Lancet Respiratory Medicine
- Article number
- .
- First page
- 499
- Volume
- 6
- Issue
- 7
- ISSN
- 2213-2600
- Open access status
- Compliant
- Month of publication
- May
- Year of publication
- 2018
- URL
-
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(18)30201-7/fulltext?showall=true=
- Supplementary information
-
https://doi.org/10.1016/S2213-2600(18)30201-7
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
24
- Research group(s)
-
B - Respiratory
- Citation count
- 57
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- -
- Author contribution statement
- Corresponding Author
- Non-English
- No
- English abstract
- -
